Impaired driving ability adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 11,206 adverse event reports that record the MedDRA preferred term Impaired driving ability. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 597 reports in the 12 months to June 2026 and 599 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 885 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 597 (under 0.1%) record this term. Reports for female patients were 61.1% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 103 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Impaired driving ability name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	39
Acetaminophen Oxycodone Hydrochloride		47
Alcohol		271
Alemtuzumab	CD52-directed cytolytic antibody	28
Alprazolam	Benzodiazepine	91
Ambien	gamma-Aminobutyric acid A receptor positive modulator	403
Amphetamine	Central nervous system stimulant	31
Ampyra	Potassium channel blocker	78
Aubagio	Pyrimidine synthesis inhibitor	69
Avonex	Interferon beta	63
Baclofen	gamma-Aminobutyric acid-ergic agonist	25
Botox	Acetylcholine release inhibitor	49
Buprenorphine	Partial opioid agonist	94
Buprenorphine Transdermal Patch		33
Butrans	Partial opioid agonist	45
Cannabis Sativa Subsp Indica Top		122
Celebrex	Nonsteroidal anti-inflammatory drug	47
Champix		34
Chantix	Partial cholinergic nicotinic agonist	336
Ciprofloxacin	Fluoroquinolone antibacterial	48
Clonazepam	Benzodiazepine	113
Cocaine		108
Codeine		37
Crestor	HMG-CoA reductase inhibitor	29
Cymbalta		184
Desvenlafaxine succinate	Serotonin and norepinephrine reuptake inhibitor	50
Dextroamphet Saccharat Amphet Aspartate Dextroamphet Sulfate and Amp		29
Dextroamphetamine Saccharate Amphetamine Aspartate Dextroamphetamine		221
Diazepam	Benzodiazepine	65
Dilantin	Anti-epileptic agent	45
Dilaudid	Opioid agonist	110
Dronabinol		87
Dupixent	Interleukin-4 receptor alpha antagonist	66
Effexor	Serotonin and norepinephrine reuptake inhibitor	95
Enbrel	Tumor necrosis factor blocker	111
Euthyrox		50
Fentanyl	Opioid agonist	202
Fentanyl citrate	Opioid agonist	35
Forteo	Parathyroid hormone analog	30
Gabapentin	Anti-epileptic agent	184
Heroin		85
Humira		169
Hydrocodone		27
Hydrocodone bitartrate	Opioid agonist	118
Hydrocodone bitartrate and acetaminophen	Opioid agonist	171
Hydromorphone Tablets		30
Ibuprofen	Nonsteroidal anti-inflammatory drug	27
Klonopin	Benzodiazepine	30
Lamictal	Anti-epileptic agent	47
Lamotrigine	Anti-epileptic agent	44
Levaquin		64
Lexapro	Serotonin reuptake inhibitor	28
Lipitor	HMG-CoA reductase inhibitor	78
Lisinopril	Angiotensin converting enzyme inhibitor	31
Lorazepam	Benzodiazepine	79
Lyrica		708
Marijuana		60
Methadone	Opioid agonist	63
Methamphetamine		207
Methotrexate	Folate analog metabolic inhibitor	33
Mirena	Progestin	30
Mirtazapine		37
Morphine	Opioid agonist	58
Morphine sulfate	Opioid agonist	190
MS Contin	Opioid agonist	84
Neurontin		120
Nexium	Proton pump inhibitor	35
Nordazepam		25
Novothyrox		170
Nuplazid	Atypical antipsychotic	40
Ocrevus	CD20-directed cytolytic antibody	37
Oxycodone	Opioid agonist	53
Oxycodone and acetaminophen	Opioid agonist	128
Oxycodone hydrochloride	Opioid agonist	634
OxyContin	Opioid agonist	508
Paxil	Serotonin reuptake inhibitor	58
Percocet	Opioid agonist	102
Prednisone	Corticosteroid	50
Pregabalin		67
Pristiq	Serotonin and norepinephrine reuptake inhibitor	29
Prolia	RANK ligand inhibitor	54
Remicade	Tumor necrosis factor blocker	26
Repatha	PCSK9 inhibitor	31
Rinvoq	Janus kinase inhibitor	26
Seroquel	Atypical antipsychotic	104
Skyrizi	Interleukin-23 antagonist	27
Suboxone	Opioid antagonist	95
Tecfidera		48
Teriflunomide	Pyrimidine synthesis inhibitor	49
Topamax		39
Topiramate		34
Tramadol		110
Tysabri	Integrin receptor antagonist	105
Valium	Benzodiazepine	32
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	30
Vicodin		55
Xanax	Benzodiazepine	149
Xarelto	Factor Xa inhibitor	25
Xeljanz	Janus kinase inhibitor	82
Xyrem	Central nervous system depressant	90
Zoloft	Serotonin reuptake inhibitor	42
Zolpidem	gamma-Aminobutyric acid A receptor positive modulator	46
Zolpidem tartrate	gamma-Aminobutyric acid A receptor positive modulator	30

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 49 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Impaired driving ability name, in order of name
Class	Reports with this term
Acetylcholine release inhibitor	78
Aminoketone	105
Angiotensin 2 receptor blocker	33
Angiotensin converting enzyme inhibitor	33
Anti-epileptic agent	358
Anticholinergic	25
Atypical antipsychotic	335
Benzodiazepine	584
CD20-directed cytolytic antibody	39
CD52-directed cytolytic antibody	40
Central nervous system depressant	90
Central nervous system stimulant	108
Complement inhibitor	26
Corticosteroid	125
Factor Xa inhibitor	32
Fluoroquinolone antibacterial	67
Folate analog metabolic inhibitor	39
gamma-Aminobutyric acid A receptor positive modulator	479
gamma-Aminobutyric acid-ergic agonist	29
GLP-1 receptor agonist	32
Histamine-1 receptor antagonist	52
HMG-CoA reductase inhibitor	144
Insulin analog	53
Integrin receptor antagonist	116
Interferon beta	77
Interleukin-23 antagonist	29
Interleukin-4 receptor alpha antagonist	78
Janus kinase inhibitor	108
Kinase inhibitor	56
l-Thyroxine	27
Mood stabilizer	26
Muscle relaxant	43
Nonsteroidal anti-inflammatory drug	111
Opioid agonist	2,572
Opioid antagonist	100
Parathyroid hormone analog	30
Partial cholinergic nicotinic agonist	336
Partial opioid agonist	146
PCSK9 inhibitor	37
Phosphodiesterase 5 inhibitor	31
Potassium channel blocker	92
Progestin	35
Proton pump inhibitor	62
Pyrimidine synthesis inhibitor	118
RANK ligand inhibitor	54
Serotonin and norepinephrine reuptake inhibitor	255
Serotonin reuptake inhibitor	217
Tumor necrosis factor blocker	181
Vascular endothelial growth factor inhibitor	34

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Impaired driving ability, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Impaired driving ability
Age	Reports	Share
Under 2	4	under 0.1%
2 to 11	4	under 0.1%
12 to 17	25	0.2%
18 to 44	2,255	20.1%
45 to 64	3,054	27.3%
65 to 74	1,095	9.8%
75 and over	681	6.1%
Age not given	4,088	36.5%

Sex of the patient in the reports that record Impaired driving ability
Sex	Reports	Share
Female	6,846	61.1%
Male	3,687	32.9%
Unknown or not given	673	6%

Age and sex are as the report gives them. 83.2% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Impaired driving ability: adverse event reports that record this term. https://reportedreactions.com/reaction/impaired-driving-ability/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Impaired driving ability mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page